Financial Contrast: Silexion Therapeutics (NASDAQ:SLXN) and Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS) and Silexion Therapeutics (NASDAQ:SLXN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

This table compares Krystal Biotech and Silexion Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13 million	20.92	$204.83 million	$6.85	40.36
Silexion Therapeutics	N/A	N/A	-$11.91 million	($11.10)	-0.10

Krystal Biotech has higher revenue and earnings than Silexion Therapeutics. Silexion Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Krystal Biotech and Silexion Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0	2	9	0	2.82
Silexion Therapeutics	1	1	1	0	2.00

Krystal Biotech currently has a consensus price target of $326.25, indicating a potential upside of 17.99%. Given Krystal Biotech’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Krystal Biotech is more favorable than Silexion Therapeutics.

Insider & Institutional Ownership

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 20.6% of Silexion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Krystal Biotech and Silexion Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	52.64%	18.69%	17.12%
Silexion Therapeutics	N/A	-387.82%	-144.68%

Volatility and Risk

Krystal Biotech has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500.

Summary

Krystal Biotech beats Silexion Therapeutics on 12 of the 13 factors compared between the two stocks.

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.